RVL Pharmaceuticals PLC RVLP

Market cap
$14.1M
P/E
0.0×
Older periods Sep '22 Dec '22 Mar '23 Jun '23
ROE

+8 more TTM periods

(86.13%) (80.88%) (103.18%) (182.44%)
ROA
(40.09%) (37.84%) (44.23%) (64.94%)
ROIC
(55.09%) (58.06%) (61.84%) (80.54%)
Return on Tangible Assets
(105.97%) (134.17%) (231.19%) 174.15%
Average Days of Receivables
27.99 22.25 18.48 19.10
Free Cash Flow per Share
(0.49) (0.43) (0.33) (0.48)
Free Cash Flow
(45.64) (38.56) (32.34) (47.41)
Capital Expenditures
0.13 (0.75) (1.99) (3.00)
Piotroski F-Score
4.00 3.00 2.00 2.00
Other line items
Cash ROIC
(24.78%) (24.78%) (23.38%) (47.63%)
Accounts Receivable Turnover
11.45 19.26 3.82 19.61
Accounts Payable Turnover
1.39 3.06 2.61 2.34
Inventory Turnover
11.04 11.66 18.29 9.90
Average Days of Payables
320.35 92.91 99.88 98.98
Days of Inventory on Hand
28.41 30.26 8.09 53.05
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
9.87% 7.98% 10.05% 8.40%
Selling, General and Administrative Expense of Revenue
205.90% 164.88% 200.34% 184.35%
Share Based Compensation of Revenue
9.77% 8.19% 9.05% 6.45%
Interest Coverage
0.00 0.00 0.00 0.00
Operating CF/Net income
0.86 0.73 0.54 0.65
Depreciation/Fixed assets
2.94 13.13 6.35 8.91
Capex/Depreciation
0.07 (0.04) (0.13) (0.10)
Revenue per Share
0.46 0.55 0.37 0.37
Operating CF per Share
(0.49) (0.42) (0.31) (0.45)
Capex per Share
0.00 (0.01) (0.02) (0.03)
Capex to Sales
0.00 0.02 0.05 0.08
Net Profit Margin
(124.13%) (103.96%) (152.21%) (184.91%)

Fold the line items

Columns are period end dates